PPAR Gamma Expression Levels during Development of Heart Failure in Patients with Coronary Artery Disease after Coronary Artery Bypass-Grafting

被引:6
作者
Wojtkowska, Izabela [1 ]
Tysarowski, Andrzej [2 ]
Seliga, Katarzyna [2 ]
Siedlecki, Janusz A. [2 ]
Juraszynski, Zbigniew [3 ]
Marona, Milosz [1 ]
Greszata, Lidia [1 ]
Skrobisz, Anna [1 ]
Kaminski, Karol [4 ]
Sawicki, Robert [4 ]
Stepinska, Janina [1 ]
机构
[1] Inst Cardiol, Intens Cardiac Therapy Clin, PL-04628 Warsaw, Poland
[2] Inst Oncol, Dept Mol Biol, PL-02781 Warsaw, Poland
[3] Inst Cardiol, Dept Cardiosurg & Transplantol, PL-04628 Warsaw, Poland
[4] Med Univ Bialystok, Dept Cardiol, PL-15276 Bialystok, Poland
关键词
TROGLITAZONE; ATHEROSCLEROSIS; ROSIGLITAZONE; DYSFUNCTION; MORTALITY;
D O I
10.1155/2014/242790
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Genetic research has elucidated molecular mechanisms of heart failure (HF). Peroxisome proliferator-activated receptors (PPARs) seem to be important in etiology of HF. The aim of study was to find the correlation between PPAR.. expression during development of HF in patients and coronary artery disease (CAD) after coronary artery bypass-grafting (CABG). Methods and Results. We followed up 157 patients (mean age 63) with CAD without clinical, laboratory, or echo parameters of HF who underwent CABG. Clinical and laboratory status were assessed before CABG and at 1, 12, and 24 months. During CABG slices of aorta (Ao) and LV were collected for genetic research. HF was defined as LVEF <40% or NT-proBNP >400 pg/mL or 6MWT <400 m. Patients were divided into 2 groups: with and without HF. PPAR gamma expression in Ao and LV was not increased in both groups at 2-year follow-up. Sensitivity of PPAR.. expression in Ao above 1.1075 in detection of HF was 20.5% (AUC 0.531, 95% CI 0.442-0.619). Positive predictive value (Ppv) was 85.7%. Sensitivity and specificity of PPAR gamma expression in the LV in detection of HF were 58% and 92.9%, respectively (AUC 0.540, 95% CI 0.452-0.626). Ppv was 73.2%. Conclusion. PPAR gamma expression in Ao and LV was comparable and should not be used as predictive factor for development of HF in patients with CAD after CABG.
引用
收藏
页数:5
相关论文
共 24 条
  • [11] Peroxisome proliferator-activate inhibit development of atherosclerosis in LDL receptor-deficient mice
    Li, AC
    Brown, KK
    Silvestre, MJ
    Willson, TM
    Palinski, W
    Glass, CK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) : 523 - 531
  • [12] The PPARγ-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction
    Lygate, CA
    Hulbert, K
    Monfared, M
    Cole, MA
    Clarke, K
    Neubauer, S
    [J]. CARDIOVASCULAR RESEARCH, 2003, 58 (03) : 632 - 637
  • [13] Chronic Inflammation Links Cardiovascular, Metabolic and Renal Diseases
    Manabe, Ichiro
    [J]. CIRCULATION JOURNAL, 2011, 75 (12) : 2739 - 2748
  • [14] The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques - Effects of rosiglitazone treatment
    Marfella, R
    D'Amico, M
    Esposito, K
    Baldi, A
    Di Filippo, C
    Siniscalchi, M
    Sasso, FC
    Portoghese, M
    Cirillo, F
    Cacciapuoti, F
    Carbonara, O
    Crescenzi, B
    Baldi, F
    Ceriello, A
    Nicoletti, GF
    D'Andrea, F
    Verza, M
    Coppola, L
    Rossi, F
    Glugliano, D
    [J]. DIABETES, 2006, 55 (03) : 622 - 632
  • [15] Baseline clinical and angiographic variables associated with long-term outcome after successful intracoronary stent implantation
    Mathew, V
    Grill, DE
    Scott, CG
    Garratt, KN
    Holmes, DR
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (07) : 789 - 794
  • [16] ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
    McMurray, John J. V.
    Adamopoulos, Stamatis
    Anker, Stefan D.
    Auricchio, Angelo
    Boehm, Michael
    Dickstein, Kenneth
    Falk, Volkmar
    Filippatos, Gerasimos
    Fonseca, Candida
    Angel Gomez-Sanchez, Miguel
    Jaarsma, Tiny
    Kober, Lars
    Lip, Gregory Y. H.
    Maggioni, Aldo Pietro
    Parkhomenko, Alexander
    Pieske, Burkert M.
    Popescu, Bogdan A.
    Ronnevik, Per K.
    Rutten, Frans H.
    Schwitter, Juerg
    Seferovic, Petar
    Stepinska, Janina
    Trindade, Pedro T.
    Voors, Adriaan A.
    Zannad, Faiez
    Zeiher, Andreas
    Bax, Jeroen J.
    Baumgartner, Helmut
    Ceconi, Claudio
    Dean, Veronica
    Deaton, Christi
    Fagard, Robert
    Funck-Brentano, Christian
    Hasdai, David
    Hoes, Arno
    Kirchhof, Paulus
    Knuuti, Juhani
    Kolh, Philippe
    McDonagh, Theresa
    Moulin, Cyril
    Popescu, Bogdan A.
    Reiner, Zeljko
    Sechtem, Udo
    Sirnes, Per Anton
    Tendera, Michal
    Torbicki, Adam
    Vahanian, Alec
    Windecker, Stephan
    McDonagh, Theresa
    Sechtem, Udo
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (14) : 1787 - 1847
  • [17] The peroxisome proliferator-activated receptor gamma (PPARγ) is highly expressed in human heart ventricles
    Mehrabi, MR
    Thalhammer, T
    Haslmayer, P
    Glogar, HD
    Wieselthaler, G
    Humpeler, S
    Marktl, W
    Ekmekcioglu, C
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (08) : 407 - 410
  • [18] Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
    Minamikawa, J
    Tanaka, S
    Yamauchi, M
    Inoue, D
    Koshiyama, H
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) : 1818 - 1820
  • [19] Importance of heart failure as a cause of death - Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992
    Murdoch, DR
    Love, MP
    Robb, SD
    McDonagh, TA
    Davie, AP
    Ford, I
    Capewell, S
    Morrison, CE
    McMurray, JJV
    [J]. EUROPEAN HEART JOURNAL, 1998, 19 (12) : 1829 - 1835
  • [20] Diagnostic utility of brain-natriuretic peptide for left ventricular diastolic dysfunction in asymptomatic type 2 diabetic patients
    Shimabukuro, M.
    Higa, N.
    Oshiro, Y.
    Asahi, T.
    Takasu, N.
    [J]. DIABETES OBESITY & METABOLISM, 2007, 9 (03) : 323 - 329